




Contents lists available at ScienceDirect

Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)



Brief report

## Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice

David J. Vance<sup>a</sup>, Yinghui Rong<sup>a</sup>, Robert N. Brey III<sup>b</sup>, Nicholas J. Mantis<sup>a,c,\*</sup>

<sup>a</sup> Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA

<sup>b</sup> Soligenix, Inc., Princeton, NJ, USA

<sup>c</sup> Department of Biomedical Sciences, University at Albany, Albany, NY, USA

### ARTICLE INFO

#### Article history:

Received 5 August 2014

Received in revised form

30 September 2014

Accepted 17 November 2014

Available online xxx

#### Keywords:

Toxin

Biodefense

Vaccine

Antigen

### ABSTRACT

In an effort to develop combination vaccines for biodefense, we evaluated a ricin subunit antigen, RiVax, given in conjunction with an anthrax protective antigen, DNI. The combination led to high endpoint titer antibody response, neutralizing antibodies, and protective immunity against ricin and anthrax lethal toxin. This is a natural combination vaccine, since both antigens are recombinant subunit proteins that would be given to the same target population.

© 2014 Elsevier Ltd. All rights reserved.

### 1. Introduction

The Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC) have designated more than 30 biological agents and toxins as having the potential to pose a severe threat to human health should they be deliberately released into the public sphere (<http://www.selectagents.gov/Select%20Agents%20and%20Toxins%20List.html>). In many instances, especially in the case of toxins like ricin, the onset of morbidity can occur within a matter of hours and there may be little if any opportunity to intervene therapeutically [1]. In other instances, like the dissemination of anthrax spores through the US Postal Service, the scope of an event could overwhelm public health response capabilities. For this reason, there is a concerted effort by Public Health and Department of Defense officials to develop prophylactic vaccines that could be administered to at-risk populations, including emergency first responders, medical care staff, and laboratory personnel. With a number of candidate biodefense vaccines now in Phase I and II clinical trials [2], it is an opportune moment to consider the possibility of combination vaccines as a means to ultimately minimize the total number

of injections and office visits necessary to achieve protective immunity against more than one pathogen or toxin.

Ricin is a ribosome-inactivating protein (RIP) and a member of the AB family of protein toxins [3]. Ricin's enzymatic subunit (RTA) is an RNA N-glycosidase that cleaves ribosomal RNA, leading to protein synthesis arrest and cell death. Ricin's binding subunit (RTB) mediates binding to cell surfaces via terminal galactose and N-acetyl galactosamine moieties on glycoproteins and glycolipids. Because of ricin's recent history as a biothreat agent, the development of countermeasures, including a vaccine, are of significant public health importance [2,4]. One of the leading vaccine antigen candidates is RiVax<sup>TM</sup>, a recombinant derivative of RTA whose enzymatic activity has been largely eliminated through a point mutation in a key active site residue and also contains a mutation in the site attributed to the induction of vascular leak syndrome (VLS) [5]. Parenteral vaccination of RiVax, either as an adjuvant-free formulation or adsorbed to aluminum salts, elicits RTA-specific serum IgG antibodies that are associated with both systemic and mucosal immunity to ricin in mice and non-human primates (C. Roy and R. Brey, unpublished results) [6–8]. Furthermore, the results of two Phase I clinical trials have indicated that RiVax is safe and immunogenic in humans [9,10]. A second RTA-based antigen known as RVEc is also in Phase I clinical trials and has been shown to be as effective as RiVax in eliciting immunity to ricin in a mouse model [11]. However, because of the ready availability of GMP-grade RiVax, we chose RiVax over RVEc for this specific study.

\* Corresponding author at: Division of Infectious Disease, Wadsworth Center, 120 New Scotland Avenue, Albany, NY 12208, USA. Tel.: +1 518 473 7487; fax: +1 518 402 4773.

E-mail address: [nicholas.mantis@health.ny.gov](mailto:nicholas.mantis@health.ny.gov) (N.J. Mantis).

When considering a putative combination vaccine for biodefense, we postulated that RiVax could be combined with a recombinant protective antigen (PA) vaccine antigen aimed at eliciting immunity to *Bacillus anthracis* infection. PA is an 83 kDa protein secreted by *B. anthracis* that forms heptamers on host cell surfaces and then non-covalently assembles with two other secreted bacterial proteins, edema factor (EF) and lethal factor (LF), to form edema toxin (ET) and lethal toxin (LT), respectively. ET and LT are the major virulence determinants of *B. anthracis* and blocking their action is essential in counteracting the effects of inhalational anthrax [12]. Indeed, PA is one of the primary antigenic components of the currently licensed anthrax vaccine known as Biothrax™, which consists of formalin-fixed culture filtrates of a nonencapsulated strain of *B. anthracis* that have been adsorbed to aluminum salts adjuvant. With the impending phase out of Biothrax™ in favor of more defined vaccine formulations, there are ongoing efforts to identify recombinant derivatives of PA that are safe (i.e., minimally reactogenic), immunogenic and stable [13]. One possible candidate is dominant negative inhibitor (DNI) or VeloThrax™, which is a derivative of PA with two point mutations (K397D, D425K) that impede the capacity of the protein to undergo conformational changes necessary for translocation of EF and LF into host cells [14]. DNI has been shown in mice to be effective at inducing the onset of PA-specific ET and LT neutralizing antibodies [14]. Moreover, clinical grade lots of DNI are remarkably stable in lyophilized form at high temperatures [15]. Thus, DNI constitutes a promising candidate antigen for a second-generation anthrax vaccine.

## 2. Results and discussion

To assess the feasibility of a RiVax-DNI combination vaccine, groups of female BALB/c mice, 6–8 weeks of ages ( $n=10$ /group; Jackson Laboratories, Bar Harbor, ME) were primed on day 0 and then boosted on day 14 with RiVax (10  $\mu$ g), DNI (10  $\mu$ g), or a combination of RiVax and DNI (10  $\mu$ g + 10  $\mu$ g), administered by intraperitoneal injection. Lyophilized DNI (batch 803918A; Baxter Pharmaceutical Solutions LLC, Bloomington, IN) was reconstituted in sterile water [15]. RiVax (batch 190-100L-GLP-FF-090105) was stored at  $-20^{\circ}\text{C}$  in 50% glycerol and 50% histidine buffer (10 mM histidine, 144 mM NaCl, pH 6.0) [16]. Each antigen was adsorbed to Alhydrogel® (0.85 mg/mL; InvivoGen, San Diego, CA) in histidine buffer for 3 h at  $4^{\circ}\text{C}$  prior to immunization. For the combination vaccine, DNI and RiVax were each adsorbed to Alhydrogel independently and then mixed 1-to-1 (v/v) just prior to injection. Following the second immunization, each group of animals (RiVax, DNI, and dual) was arbitrarily divided into two groups, A and B. The A groups were ultimately challenged with LT, while the B groups were challenged with ricin. Sera were collected from all immunized mice *via* the lateral tail veins on days 20 and 200, representing snapshots of the early and late (“memory”) responses to the vaccines. All animal experiments were done in strict compliance with protocols approved by the Wadsworth Center’s Institutional Animal Care and Use Committee (IACUC). Log transformed paired and unpaired *t* tests and the Mantel-Cox test were conducted with Graphpad Prism version 5.0 (San Diego, CA).

Analysis of sera collected on day 20 indicated that the RiVax-vaccinated mice had anti-ricin holotoxin IgG geometric mean titers (GMT) of  $>2.0 \times 10^5$  and, as expected, no detectable serum antibodies against PA (Fig. 1A; Table 1; Table S1). On day 200, the ricin-specific IgG GMT had declined by roughly half, as compared to day 20. On day 20, DNI-vaccinated mice had anti-PA GMT of  $1.8 \times 10^5$ , and no detectable serum antibodies against ricin. Analysis of day 200 sera indicated that PA-specific antibody titers in DNI-vaccinated were unchanged, and in some mice slightly increased, as compared to day 20. Finally, the dual RiVax-DNI

**Table 1**  
Ricin- and PA-specific serum antibody geometric mean titers following immunization.

Immunization	Ricin <sup>a</sup>		PA <sup>a</sup>	
	Day 20	Day 200	Day 20	Day 200
RiVax	204,800	109,750	1 <sup>b</sup>	1
DNI	1	1	189,619	175,564
Dual	126,069	95,543	44,572	54,875

<sup>a</sup> Coating antigen used in ELISAs, as described in the text.

<sup>b</sup> When no antigen-specific serum IgG titers were detectable, an arbitrary value of 1 was assigned for the purpose calculating the geometric mean titers.

vaccinated mice had both ricin- and PA-specific serum antibodies on days 20 and 200, indicating that the subunit antigens were not incompatible with each other (Fig. 1A; Table 1; Table S1). However, on day 20, the ricin- and PA-specific serum IgG GMTs in the group of dual vaccinated mice were roughly half of that observed in mice immunized with the individual antigens, demonstrating that the magnitudes of the antibody responses were negatively affected ( $p < 0.01$ ) by the combination of the two antigens. By day 200, anti-ricin antibody titers in the dual immunized mice were still lower than in the mice that received RiVax only, but these differences were not statistically significant ( $p = 0.55$ ). In contrast, anti-PA titers remained lower in the dual immunized mice, as compared to DNI immunized animals ( $p < 0.0001$ ), indicating that the immunogenicity of DNI is adversely affected when combined with RiVax.

We next assessed ricin- and LT toxin-neutralizing activities (TNA) elicited by RiVax, DNI, or the combination of RiVax and DNI vaccination regimens. Ricin TNA was determined using a Vero cell cytotoxicity assay [17]. LT-neutralizing activity was determined using a J774 murine macrophage cell-based assay [15,18]. Neutralization activity was defined as the highest dilution of serum that protected  $\geq 50\%$  of the cells from toxin-induced death, a value commonly referred to as the TCIC<sub>50</sub>. In day 20 serum samples, the RiVax-vaccinated mice had no detectable TNA, with the exception of one animal that had a neutralizing titer of 100 (Fig. 1B; Table 2; Table S1). On day 200, however, the neutralizing GMT in this group of animals was  $>450$ , with individual titers ranging from 100 to 1600. As expected, RiVax-immunized mice had no detectable serum LT-neutralizing activity at either day 20 or 200. DNI vaccination, on the other hand, was highly effective at eliciting the early onset of LT-neutralizing titers, as evidenced by neutralizing GMT of 1087 and 1728 on days 20 and 200, respectively (Fig. 1B; Table 2; Table S1). No detectable ricin-neutralizing activity was evident in the sera of DNI-vaccinated mice at either time point, confirming the absence of cross-reactivity between RiVax and DNI.

The combination of RiVax and DNI was successful at eliciting TNA against both ricin and LT, although the magnitude of the LT response was significantly dampened as compared to mice that received DNI alone ( $p < 0.05$ ; Table 2; Fig. 1B; Fig. S1). Specifically, the LT-neutralizing GMT in the sera of dual immunized mice was 205 and 800 on days 20 and 200, respectively, as compared to 1087

**Table 2**  
Toxin-neutralizing titers in RiVax-, DNI- and Dual-immunized groups of mice.

Group	Day 20–LT TNA			Day 200–LT TNA			Day 200–Ricin TNA		
	Total	A <sup>a</sup>	B	Total	A	B	Total	A	B
RiVax	1 <sup>b</sup>	1	1	1	1	1	459	528	400
DNI	1087	1213	951	1728	1600	1903	1	1	1
Dual	205	264	159	800	606	1056	429	696	264

<sup>a</sup> Each group of mice (left column) was arbitrarily divided into two subsets, A and B. Shown are the neutralizing titers from sera collected on day 20 or 200 from the all mice in a group (as “Total”) or as the specific A and B subsets.

<sup>b</sup> Mice lacking detectable toxin-neutralizing serum antibody titers were arbitrarily assigned a value of 1 for the purpose of statistical analysis.

Download English Version:

<https://daneshyari.com/en/article/10965939>

Download Persian Version:

<https://daneshyari.com/article/10965939>

[Daneshyari.com](https://daneshyari.com)